FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

BMS Gains Approval for Lung Cancer NDA

FDA approves a Bristol Myers Squibb NDA for Augtyro (repotrectinib) for treating adult patients with locally advanced or metastatic ROS1-positive non-...

latest-news-card-1
Federal Register

Regulatory Review Determination on Rozlytrek Corrected

Federal Register notice: FDA corrects a notice that appeared in the 7/8/2022 Federal Register that announced an agency determination of the regulatory...

latest-news-card-1
Federal Register

Panel to Tackle Pulse Oximeter Quality

Federal Register notice: FDA announces a 2/2/2024 advisory committee meeting to discuss pulse oximeter quality.

Medical Devices

Device Discontinuance and 506J List Guidances

FDA issues one final and one draft guidance related to Section 506J notifications of medical device shortages.

latest-news-card-1
Human Drugs

FDA Publishes 40 Product-Specific Guidances

FDA publishes 22 new and 18 revised product-specific guidances for developing generic drugs.

latest-news-card-1
Medical Devices

Device Computational Modeling Credibility Guide

FDA publishes a guidance to help in assessing the credibility of computational modeling and simulation in medical device submissions.

latest-news-card-1
Human Drugs

U.S. Drug Shortages Increasing: Report

An Iqvia Institute report says drug shortages continue to increase in the U.S., with the number of new shortages outpacing the number resolved.

latest-news-card-1
Human Drugs

Provide Covid Therapeutics Distribution Info: Califf

FDA commissioner Robert Califf calls on the Healthcare Distribution Alliance to give aggregate information to the agency on the distribution of Covid ...

FDA General

2 Consent Decrees Against Supplement Marketers

The central Utah federal court approves two consent decrees of permanent injunction against Evig LLC and Premium Production LLC over their distributio...

Human Drugs

SpringWorks Filing Mirdametinib NDA in 2024

After releasing promising clinical data, SpringWorks Therapeutics says it will file an NDA in the first half of 2024 for mirdametinib, an investigatio...